The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
640
MEBEVERINE VERSUS PLACEBO IN ADOLESCENTS WITH IRRITABLE BOWEL SYNDROME OR FUNCTIONAL ABDOMINAL PAIN AND THE INFLUENCE OF LABELING: A 2X2 RANDOMIZED CONTROLLED TRIAL.
Date
May 20, 2024
Abstract Background: Effective and safe pharmacologic treatments are lacking for children with Irritable Bowel Syndrome (IBS) and Functional Abdominal Pain – Not otherwise specified (FAP-NOS). We evaluated the efficacy and safety of mebeverine, an antispasmodic agent. In addition, the effect of labeling on mebeverine and placebo was investigated. Methods: In this placebo controlled, double blind, randomized trial 269 children (aged 12-18 years old) with IBS or FAP-NOS were assigned to mebeverine (at a dose of 200 mg twice daily) or placebo for 8 weeks and 4 weeks follow-up. Study medication was labeled as “you may receive mebeverine or placebo” (blinded trial label) or “you receive mebeverine” (mebeverine label), thus creating four treatment groups: 1) mebeverine with a blinded trial label, 2) mebeverine with a mebeverine label, 3) placebo with a blinded trial label and 4) placebo with a mebeverine label. The primary end point was the proportion of patients who achieved treatment success (a ≥50% reduction of both abdominal pain intensity and pain frequency) after 8 weeks. The key secondary outcome measure was adequate relief of IBS/FAP-NOS symptoms. Results: Treatment success was similar between patients receiving mebeverine (group 1 and 2) and placebo (group 3 and 4) (23.9% vs. 23.9%, P=0.92). Significantly more patients in treatment groups with mebeverine label (group 2 and 4) achieved treatment success compared to treatment groups with blinded trial label (group 1 and 3) (32.9% vs. 15.0%, P=0.002). Similar proportions of patients receiving mebeverine (group 1 and 2) or placebo (group 3 and 4) reported adequate relief of their IBS/FAP-NOS symptoms (43.7% vs. 47.3% P=0.52). Significant more patients in treatment groups with mebeverine label (group 2 and 4) reached adequate relief than patients in treatment groups with blinded trial label (group 1 and 3) (52.8% vs. 38.3% P=0.02). Adverse events were infrequent and equal between groups. Conclusions: Mebeverine was not superior compared to placebo for the treatment of pediatric IBS and FAP-NOS. However, being convinced to receive mebeverine enhanced treatment success and adequate relief rates significantly compared to not knowing. This may have implications for future pediatric drug trials.
SOCIETY: AGA Several advances are occurring in the pediatric endoscopy landscape -from techniques to quality improvement. This will be a cutting-edge session…
BACKGROUND: Recent studies suggest links between _Clostridioides difficile_ infection (CDI) and liver disorders, with non-alcoholic fatty liver disease (NAFLD) increasing CDI risk and CDI exacerbating the progression and prognosis of liver cirrhosis. Moreover, gut dysbiosis, often leading to _C…